Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT01062399 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

279

Enrollment

NETWORK

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: concurrent RAD001 10 mg/day
DRUG: concurrent temozolomide
RADIATION: Radiation therapy
DRUG: concurrent RAD001 2.5 mg/day
DRUG: concurrent RAD001 5 mg/day
DRUG: post-radiation RAD001 10 mg/day
DRUG: post-radiation temozolomide

Sponsor

Radiation Therapy Oncology Group

Collaborators

[object Object]
[object Object]